Categories: DNANewsPharmaceutical

Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced that Stephen Pham, Ph.D., senior vice president of product development at Avalyn, will give a keynote address during the Formulation & Delivery U.S. 2023 Conference being held October 2-3, 2023, in San Diego, CA. Dr. Pham will discuss the development of inhaled drug-device combinations for the treatment of pulmonary fibrosis.

Details for Dr. Pham’s keynote address are as follows:

Keynote Title: Bringing Beautiful Breaths of Life to Patients with Pulmonary Fibrosis
Date and Time: Monday, October 2, 2023, at 8:55 a.m. PT
Location: Doubletree by Hilton San Diego Mission Valley, Conference Room 4

Full program details can be accessed via the conference website.

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com.

Contacts:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com

Cara Mayfield
THRUST Strategic Communications
cara@thrustsc.com

Staff

Recent Posts

Waystar to Present at Goldman Sachs Communacopia + Technology Conference

LEHI, Utah and LOUISVILLE, Ky., Aug. 26, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider…

3 hours ago

Waters Corporation to Present at the Wells Fargo Healthcare Conference

MILFORD, Mass., Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters…

3 hours ago

GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company…

3 hours ago

Red Rover Health Celebrated in KLAS Research’s Emerging Company Spotlight Report

DES MOINES, Iowa, Aug. 26, 2025 /PRNewswire/ -- KLAS Research has released its latest Emerging Company…

3 hours ago

Unisom® Teams Up with Football Legend Julian Edelman to Help Fantasy Football Fans Get a Better Night’s Rest

The brand launches Sleeper Pickz in partnership with Julian Edelman to help fans put fantasy…

3 hours ago

TheChallenge.org: New Study by Finds Reducing Phone Use is Over Twice as Hard as Enduring a Daily Ice Bath

WARSAW, Poland, Aug. 26, 2025 /PRNewswire/ -- A new social study involving 9,150 participants from…

3 hours ago